JACC-Heart Failure

Papers
(The H4-Index of JACC-Heart Failure is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Eating to Prevent Both Heart and Planetary Failure214
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States165
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction159
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction149
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status115
Correction94
Reply91
Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure83
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure75
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death71
Editorial Board70
Wearable Remote Patient Monitoring Devices65
Developing a System for Best Performance for Cardiac Transplantation62
Reply62
Long-Term Effects of Sotatercept on Right Ventricular Function60
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia58
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies53
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction52
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure51
Predictors of Incident Heart Failure Diagnosis Setting51
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans49
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome49
Opportunities for Change in Home Health Care in Heart Failure48
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF48
Curing Ourselves of Toxic Positivity for Hospital-at-Home46
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype46
Challenges Addressing Prognosis in Advanced Heart Failure44
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function44
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis43
Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction41
A Woman's Work Is Never Done41
Thank You for the Privilege41
The Urgent Need for More Cardiac Rehabilitation in the Aim to “Preserve” Patients With Heart Failure40
Racial and Genetic Differences40
Reply40
Mitral Regurgitation in Heart Failure38
Inhibiting Both Neprilysin and Phosphodiesterase Type 937
0.17368006706238